Esperion Therapeutics, Inc.
esperion.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2026 10-Q, filed May 8, 2026. Its latest SEC filing is a SCHEDULE 13G from Aug 13, 2026.
10-Q for Q1 FY2026, filed May 8, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Sells oral, non-statin medicines for people with elevated LDL cholesterol who are at risk of cardiovascular disease.
10-K for FY2025, filed Mar 10, 2026
How Did They Make Money?
U.S. wholesalers buy NEXLETOL and NEXLIZET, with sales counted when they physically receive the medicines. Collaboration revenue includes upfront and milestone payments, royalties on partner sales, and product supply; regulatory work is counted as it progresses, supply when partners receive it, and royalties as partner sales occur.
10-K for FY2025, filed Mar 10, 2026The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The…View ↗
The terms of the agreements typically include consideration to be provided to the Company in the form of non-refundable up-front payments…View ↗
At the inception of a contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in…View ↗
Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are…View ↗
The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S and recognizes revenue at the point in time when the customer is deemed…View ↗
-
10-K for FY2025, filed Mar 10, 2026
FY2025 revenue by product or service ↗
$403.1M
-
10-K for FY2025, filed Mar 11, 2026
$403.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 10, 2026 |
40%
FY2022: 74%
|
Product, FY2025
$159.6M Sources
|
Sold outright |
|
Collaboration Revenue
|
60%
FY2022: 26%
|
Collaboration Revenue, FY2025
$243.6M Sources
|
Who Were Their Customers?
In the U.S., wholesalers buy NEXLETOL and NEXLIZET; outside the U.S., partners develop, manufacture and commercialize the products under collaboration agreements.
10-K for FY2025, filed Mar 10, 2026
Did Revenues Turn Into Profits?
No. It lost $22.7M in FY2025.
10-K for FY2025, filed Mar 11, 2026
$60.3MView ↗
10-K for FY2025, filed Mar 11, 2026
−$22.7MView ↗
10-K for FY2025, filed Mar 11, 2026
−$13.1MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 9, 2026
−$25.2MView ↗
- ▼ −38% (Loss)
- vs −$40.5M in Q1 FY2025
10-Q for Q1 FY2026, filed May 8, 2026
Open tableView ↗
-
Jul 13, 2026
Esperion's acquisition by ARCHIMED was completed
Holders' contingent value rights can receive up to $100 million in contingent payments upon specified milestones.
Sources
8-K, filed Jul 13, 2026
On July 13, 2026, pursuant to the Merger Agreement, Parent and the Company entered into a Contingent Value Rights Agreement with the Rights…View ↗
-
Apr 2, 2026
Esperion completed its acquisition of Corstasis
The deal included $75,000,000 upfront, plus up to $180,000,000 in milestones and future royalty and licensing payments.
Sources
8-K, filed Apr 2, 2026
The aggregate up-front consideration for the transactions contemplated by the Merger Agreement (the “Transactions”) was $75,000,000 in…View ↗
Grew. Revenue grew 5.1x in 4 years, from $78.4M in FY2021 to $403.1M in FY2025, about 51% a year.
Broader treatment group
Earlier, the U.S. products were described for people with inherited high cholesterol or established cardiovascular disease who needed additional cholesterol lowering. The latest report also describes their use for high-risk adults without established disease and adults with primary high cholesterol.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Mar 10, 2026Our lead products NEXLETOL® (bempedoic acid) tablets and NEXLIZET® (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin…View ↗
Loading...
